A Comprehensive Review of Hepatorenal Syndrome
Andrew Bland, MD, MBA, MS
This comprehensive review examines the pathophysiology, diagnosis, management, and outcomes of kidney disease in end-stage liver disease, with particular emphasis on hepatorenal syndrome (HRS). Recent advances in our understanding have led to significant changes in nomenclature and diagnostic criteria, with HRS type 1 now designated as HRS-AKI (acute kidney injury). The effectiveness of dialysis in this population remains controversial, with mortality rates exceeding 60% at one year. Portal hypertension poses additional challenges, including increased risks of intradialytic hypotension and potential variceal bleeding. This review synthesizes recent literature from 2021–2024 to provide current perspectives on managing this complex condition.
Keywords: hepatorenal syndrome, end-stage liver disease, cirrhosis, dialysis, portal hypertension, acute kidney injury
The relationship between hepatic and renal function represents one of the most intricate physiological relationships in human medicine. In end-stage liver disease, kidney dysfunction emerges as a frequent and often life-threatening complication that significantly impacts patient outcomes. Among the various forms of kidney dysfunction encountered in this population, hepatorenal syndrome stands as the most challenging, representing the convergence of two major organ failures with profound implications for patient survival and management.
Hepatorenal syndrome has recently undergone substantial revision in its definition and classification. The traditional dichotomy of HRS type 1 and type 2 has been replaced with a more nuanced framework that reflects our evolving understanding of this condition's pathophysiology. This review provides a comprehensive analysis of current knowledge regarding kidney disease in end-stage liver disease, drawing from recent literature published between 2021 and 2024.
The development of kidney dysfunction in cirrhosis represents a complex interplay of hemodynamic, neurohormonal, and inflammatory processes. Portal hypertension, the hallmark of advanced cirrhosis, initiates a cascade of events that ultimately compromise renal perfusion. The primary mechanism involves splanchnic arterial vasodilation, which leads to a state of "effective hypovolemia" despite total body fluid overload.1
This hemodynamic derangement activates multiple compensatory mechanisms, including the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and non-osmotic vasopressin release. While these systems initially attempt to maintain systemic blood pressure, they paradoxically result in intense renal vasoconstriction, ultimately reducing glomerular filtration rate (GFR) and renal blood flow.2
Recent research has illuminated the role of inflammation in HRS pathogenesis. The dysregulated immune response associated with acute-on-chronic liver failure contributes to systemic inflammation, which may condition the development of extrahepatic organ dysfunction, including kidney injury.2 This inflammatory process may explain why some patients with cirrhosis develop HRS while others do not, despite similar hemodynamic profiles.
A paradigm shift has occurred in the classification of HRS, reflecting advances in our understanding of this condition. The International Club of Ascites (ICA) has revised its nomenclature, with HRS type 1 now designated as HRS-AKI.2 This change represents more than semantic modification; it facilitates earlier recognition and treatment initiation by eliminating arbitrary creatinine thresholds.
The current classification encompasses:
This classification acknowledges that cirrhotic patients can manifest various phenotypes of kidney dysfunction, ranging from purely functional (HRS) to structural (acute tubular necrosis) causes.2
The diagnosis of HRS-AKI now employs dynamic criteria based on serum creatinine changes, removing the previous requirement for an absolute creatinine threshold. This modification enables the identification of patients who may have been previously overlooked due to sarcopenia-related baseline creatinine values that underestimated true renal function.2
Comprehensive analysis of a large cohort (n=7,830) of patients with HRS requiring maintenance dialysis revealed:4
Notably, recent evidence has challenged previous assumptions regarding outcome differences between HRS-AKI and acute tubular necrosis (ATN) in dialysis-dependent patients. Among those not listed for liver transplantation, mortality rates were comparable, approaching 84–85% in both groups.5
| Factor | Impact |
|---|---|
| Age | Younger patients (<30 years) demonstrate superior recovery rates |
| Transplant candidacy | Patients listed for liver transplantation have improved survival |
| Dialysis modality | Patients receiving peritoneal dialysis were less likely to recover kidney function |
The cornerstone of HRS-AKI treatment remains pharmacological, with vasoconstrictive medications — particularly terlipressin — combined with albumin administration.6 Terlipressin's recent approval in the United States represents a significant advance, offering the first FDA-approved treatment specifically for HRS-AKI.9
Renal replacement therapy in HRS serves primarily as a bridging intervention rather than definitive treatment. Indications include:
Patients with cirrhosis and portal hypertension face heightened risk for intradialytic hypotension (IDH), defined as a rapid decrease in systolic blood pressure ≥20 mmHg or mean arterial pressure ≥10 mmHg requiring intervention.8 While IDH affects 10–12% of chronic kidney disease patients undergoing outpatient dialysis,7 the prevalence in cirrhotic patients is substantially higher due to:
The risk of variceal bleeding during dialysis in patients with portal hypertension represents a significant clinical concern. Contributing factors include:
To minimize complications associated with dialysis in portal hypertensive patients:
Emerging evidence suggests significant heterogeneity in HRS presentation and outcomes, supporting the development of personalized treatment algorithms. Factors such as age, ethnicity, and underlying liver disease etiology influence both treatment response and prognosis.4
Research continues to focus on identifying biomarkers that enable early HRS detection and accurate differentiation from other causes of AKI in cirrhosis.13 These advances may facilitate earlier intervention and improved outcomes.
The molecular adsorbent recirculating system (MARS) represents a promising development, offering simultaneous hepatic and renal support through albumin dialysis.9 However, its role in improving HRS outcomes remains limited, requiring further validation.
The management of kidney disease in end-stage liver disease demands a nuanced approach that balances aggressive intervention with realistic prognostic expectations. Key considerations include:
A multidisciplinary approach involving hepatology, nephrology, and critical care specialists remains essential for optimizing outcomes while maintaining quality of life considerations. As our understanding advances, the hope is that earlier intervention and more targeted therapies will improve the dismal prognosis that currently characterizes this condition.
| Reference | Year | Source Type | Evidence Level | Confidence |
|---|---|---|---|---|
| 1. Amathieu et al. | 2023 | PMC Article | Systematic Review | 4/5 |
| 2. Bañares et al. | 2023 | World J Hepatol | Comprehensive Review | 5/5 |
| 3. Pyrsopoulos et al. | 2023 | Gastro Hep | Clinical Review | 4/5 |
| 4. Eason et al. | 2022 | CJASN | Large Cohort Study | 5/5 |
| 5. Allegretti & Ginès | 2021 | Kidney360 | Expert Opinion | 3/5 |
| 9. Ko et al. | 2023 | Clin Mol Hepatol | Comprehensive Review | 4/5 |
| 11. Kaplan et al. | 2024 | Hepatology | Practice Guidance | 5/5 |
All references except one are peer-reviewed medical literature. 79% of references are from 2021–2024. High proportion of high-impact journals in hepatology and nephrology.
© Urine Nephrology Now — Clinical Mastery Series